ZBTB20-AS3

Across TCGA pan-cancer cohorts, ZBTB20-AS3 RNA differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of ZBTB20-AS3’s most consistent transcriptional readouts.

The strongest signal is observed in cholangiocarcinoma (CHOL), where ZBTB20-AS3 RNA is repressed in tumor relative to normal tissue. In most cancer types ZBTB20-AS3 is over-expressed in tumor, although a few such as CHOL and KIRP show the opposite, repressed pattern.

CHOL, KIRP, and LUSC are the cancer types where ZBTB20-AS3 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ZBTB20-AS3 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CHOL	Female	All	−0.156	.001	4	view →
KIRP	All	All	−0.070	.003	4	view →
LUSC	All	All	−0.036	.016	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

ZBTB20-AS3–CHOL

Open the CHOL breakdown →